nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0291	0.0598	CbGbCtD
Dasatinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0264	0.0541	CbGbCtD
Dasatinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0264	0.0541	CbGbCtD
Dasatinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0253	0.0519	CbGbCtD
Dasatinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0213	0.0437	CbGbCtD
Dasatinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0196	0.0401	CbGbCtD
Dasatinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0193	0.0395	CbGbCtD
Dasatinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0193	0.0395	CbGbCtD
Dasatinib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0169	0.0346	CbGbCtD
Dasatinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0166	0.0341	CbGbCtD
Dasatinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0161	0.0331	CbGbCtD
Dasatinib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0159	0.0325	CbGbCtD
Dasatinib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0159	0.0325	CbGbCtD
Dasatinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0146	0.03	CbGbCtD
Dasatinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0146	0.03	CbGbCtD
Dasatinib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0143	0.0294	CbGbCtD
Dasatinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0139	0.0285	CbGbCtD
Dasatinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0125	0.0257	CbGbCtD
Dasatinib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.012	0.0247	CbGbCtD
Dasatinib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0109	0.0223	CbGbCtD
Dasatinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0108	0.0222	CbGbCtD
Dasatinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0105	0.0216	CbGbCtD
Dasatinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00951	0.0195	CbGbCtD
Dasatinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00951	0.0195	CbGbCtD
Dasatinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00911	0.0187	CbGbCtD
Dasatinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00884	0.0181	CbGbCtD
Dasatinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00831	0.0171	CbGbCtD
Dasatinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00831	0.0171	CbGbCtD
Dasatinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00751	0.0154	CbGbCtD
Dasatinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00751	0.0154	CbGbCtD
Dasatinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00705	0.0145	CbGbCtD
Dasatinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00649	0.0133	CbGbCtD
Dasatinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0063	0.0129	CbGbCtD
Dasatinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00569	0.0117	CbGbCtD
Dasatinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00569	0.0117	CbGbCtD
Dasatinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00546	0.0112	CbGbCtD
Dasatinib—JAK2—bone marrow—acquired immunodeficiency syndrome	0.000262	0.00174	CbGeAlD
Dasatinib—MAP4K5—blood—acquired immunodeficiency syndrome	0.000261	0.00174	CbGeAlD
Dasatinib—MAP3K3—blood—acquired immunodeficiency syndrome	0.000261	0.00174	CbGeAlD
Dasatinib—JAK2—spinal cord—acquired immunodeficiency syndrome	0.000261	0.00174	CbGeAlD
Dasatinib—EPHA5—brain—acquired immunodeficiency syndrome	0.000261	0.00174	CbGeAlD
Dasatinib—LYN—brain—acquired immunodeficiency syndrome	0.000259	0.00173	CbGeAlD
Dasatinib—FYN—bone marrow—acquired immunodeficiency syndrome	0.000258	0.00172	CbGeAlD
Dasatinib—ZAK—lymph node—acquired immunodeficiency syndrome	0.000257	0.00171	CbGeAlD
Dasatinib—FYN—spinal cord—acquired immunodeficiency syndrome	0.000257	0.00171	CbGeAlD
Dasatinib—FMO3—vagina—acquired immunodeficiency syndrome	0.000256	0.00171	CbGeAlD
Dasatinib—YES1—lymphoid tissue—acquired immunodeficiency syndrome	0.000256	0.0017	CbGeAlD
Dasatinib—SIK1—nervous system—acquired immunodeficiency syndrome	0.000256	0.0017	CbGeAlD
Dasatinib—BMPR1B—brain—acquired immunodeficiency syndrome	0.000255	0.0017	CbGeAlD
Dasatinib—MAP3K19—brain—acquired immunodeficiency syndrome	0.000255	0.0017	CbGeAlD
Dasatinib—BTK—brain—acquired immunodeficiency syndrome	0.000254	0.00169	CbGeAlD
Dasatinib—EPHA4—nervous system—acquired immunodeficiency syndrome	0.000253	0.00169	CbGeAlD
Dasatinib—YES1—digestive system—acquired immunodeficiency syndrome	0.000253	0.00168	CbGeAlD
Dasatinib—EPHB4—vagina—acquired immunodeficiency syndrome	0.000253	0.00168	CbGeAlD
Dasatinib—MAP3K3—bone marrow—acquired immunodeficiency syndrome	0.000253	0.00168	CbGeAlD
Dasatinib—MAP4K5—bone marrow—acquired immunodeficiency syndrome	0.000253	0.00168	CbGeAlD
Dasatinib—MAPK14—lung—acquired immunodeficiency syndrome	0.000252	0.00168	CbGeAlD
Dasatinib—MAP4K5—spinal cord—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—MAP3K3—spinal cord—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—FGR—lung—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—LCK—lung—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—JAK2—vagina—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—ERBB3—nervous system—acquired immunodeficiency syndrome	0.000251	0.00167	CbGeAlD
Dasatinib—TNK2—brain—acquired immunodeficiency syndrome	0.00025	0.00167	CbGeAlD
Dasatinib—EPHB6—blood—acquired immunodeficiency syndrome	0.000249	0.00166	CbGeAlD
Dasatinib—MAP3K2—nervous system—acquired immunodeficiency syndrome	0.000248	0.00165	CbGeAlD
Dasatinib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000248	0.00165	CbGeAlD
Dasatinib—KIT—skin of body—acquired immunodeficiency syndrome	0.000248	0.00165	CbGeAlD
Dasatinib—EPHA2—vagina—acquired immunodeficiency syndrome	0.000248	0.00165	CbGeAlD
Dasatinib—FYN—vagina—acquired immunodeficiency syndrome	0.000248	0.00165	CbGeAlD
Dasatinib—BMPR1B—lymph node—acquired immunodeficiency syndrome	0.000247	0.00164	CbGeAlD
Dasatinib—SRC—lymphoid tissue—acquired immunodeficiency syndrome	0.000246	0.00164	CbGeAlD
Dasatinib—SIK1—central nervous system—acquired immunodeficiency syndrome	0.000246	0.00164	CbGeAlD
Dasatinib—ABL1—retina—acquired immunodeficiency syndrome	0.000246	0.00164	CbGeAlD
Dasatinib—BTK—lymph node—acquired immunodeficiency syndrome	0.000246	0.00163	CbGeAlD
Dasatinib—EPHA4—central nervous system—acquired immunodeficiency syndrome	0.000244	0.00162	CbGeAlD
Dasatinib—SRC—digestive system—acquired immunodeficiency syndrome	0.000243	0.00162	CbGeAlD
Dasatinib—FMO3—lung—acquired immunodeficiency syndrome	0.000243	0.00161	CbGeAlD
Dasatinib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000242	0.00161	CbGeAlD
Dasatinib—TNK2—lymph node—acquired immunodeficiency syndrome	0.000242	0.00161	CbGeAlD
Dasatinib—MAP4K5—vagina—acquired immunodeficiency syndrome	0.000242	0.00161	CbGeAlD
Dasatinib—MAP3K3—vagina—acquired immunodeficiency syndrome	0.000242	0.00161	CbGeAlD
Dasatinib—ERBB3—central nervous system—acquired immunodeficiency syndrome	0.000241	0.00161	CbGeAlD
Dasatinib—YES1—blood—acquired immunodeficiency syndrome	0.000241	0.0016	CbGeAlD
Dasatinib—EPHB6—spinal cord—acquired immunodeficiency syndrome	0.00024	0.0016	CbGeAlD
Dasatinib—MAP3K2—central nervous system—acquired immunodeficiency syndrome	0.000239	0.00159	CbGeAlD
Dasatinib—EPHB4—lung—acquired immunodeficiency syndrome	0.000239	0.00159	CbGeAlD
Dasatinib—JAK2—lung—acquired immunodeficiency syndrome	0.000237	0.00158	CbGeAlD
Dasatinib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000236	0.00157	CbGeAlD
Dasatinib—TESK1—brain—acquired immunodeficiency syndrome	0.000236	0.00157	CbGeAlD
Dasatinib—EPHA2—lung—acquired immunodeficiency syndrome	0.000235	0.00156	CbGeAlD
Dasatinib—FYN—lung—acquired immunodeficiency syndrome	0.000234	0.00156	CbGeAlD
Dasatinib—MAPK14—nervous system—acquired immunodeficiency syndrome	0.000234	0.00155	CbGeAlD
Dasatinib—YES1—bone marrow—acquired immunodeficiency syndrome	0.000233	0.00155	CbGeAlD
Dasatinib—FGR—nervous system—acquired immunodeficiency syndrome	0.000233	0.00155	CbGeAlD
Dasatinib—YES1—spinal cord—acquired immunodeficiency syndrome	0.000232	0.00155	CbGeAlD
Dasatinib—SRC—blood—acquired immunodeficiency syndrome	0.000232	0.00154	CbGeAlD
Dasatinib—STK36—brain—acquired immunodeficiency syndrome	0.000232	0.00154	CbGeAlD
Dasatinib—EPHB3—brain—acquired immunodeficiency syndrome	0.000232	0.00154	CbGeAlD
Dasatinib—EPHB6—vagina—acquired immunodeficiency syndrome	0.000231	0.00154	CbGeAlD
Dasatinib—MAP4K5—lung—acquired immunodeficiency syndrome	0.000229	0.00152	CbGeAlD
Dasatinib—MAP3K3—lung—acquired immunodeficiency syndrome	0.000229	0.00152	CbGeAlD
Dasatinib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000228	0.00152	CbGeAlD
Dasatinib—TESK1—lymph node—acquired immunodeficiency syndrome	0.000228	0.00151	CbGeAlD
Dasatinib—MAPK14—central nervous system—acquired immunodeficiency syndrome	0.000225	0.0015	CbGeAlD
Dasatinib—FMO3—nervous system—acquired immunodeficiency syndrome	0.000225	0.00149	CbGeAlD
Dasatinib—LIMK2—brain—acquired immunodeficiency syndrome	0.000224	0.00149	CbGeAlD
Dasatinib—STK36—lymph node—acquired immunodeficiency syndrome	0.000224	0.00149	CbGeAlD
Dasatinib—EPHB3—lymph node—acquired immunodeficiency syndrome	0.000224	0.00149	CbGeAlD
Dasatinib—FGR—central nervous system—acquired immunodeficiency syndrome	0.000224	0.00149	CbGeAlD
Dasatinib—YES1—vagina—acquired immunodeficiency syndrome	0.000223	0.00149	CbGeAlD
Dasatinib—SRC—spinal cord—acquired immunodeficiency syndrome	0.000223	0.00149	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	0.000221	0.00147	CbGeAlD
Dasatinib—JAK2—nervous system—acquired immunodeficiency syndrome	0.00022	0.00146	CbGeAlD
Dasatinib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.000219	0.00146	CbGeAlD
Dasatinib—EPHB6—lung—acquired immunodeficiency syndrome	0.000219	0.00145	CbGeAlD
Dasatinib—CSF1R—digestive system—acquired immunodeficiency syndrome	0.000218	0.00145	CbGeAlD
Dasatinib—STK35—brain—acquired immunodeficiency syndrome	0.000217	0.00145	CbGeAlD
Dasatinib—EPHA2—nervous system—acquired immunodeficiency syndrome	0.000217	0.00145	CbGeAlD
Dasatinib—FYN—nervous system—acquired immunodeficiency syndrome	0.000217	0.00144	CbGeAlD
Dasatinib—LIMK2—lymph node—acquired immunodeficiency syndrome	0.000217	0.00144	CbGeAlD
Dasatinib—FMO3—central nervous system—acquired immunodeficiency syndrome	0.000216	0.00144	CbGeAlD
Dasatinib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000216	0.00144	CbGeAlD
Dasatinib—CSK—brain—acquired immunodeficiency syndrome	0.000216	0.00144	CbGeAlD
Dasatinib—MAP2K5—blood—acquired immunodeficiency syndrome	0.000213	0.00142	CbGeAlD
Dasatinib—HCK—brain—acquired immunodeficiency syndrome	0.000213	0.00142	CbGeAlD
Dasatinib—MAP4K5—nervous system—acquired immunodeficiency syndrome	0.000212	0.00141	CbGeAlD
Dasatinib—MAP3K3—nervous system—acquired immunodeficiency syndrome	0.000212	0.00141	CbGeAlD
Dasatinib—ABL2—brain—acquired immunodeficiency syndrome	0.000212	0.00141	CbGeAlD
Dasatinib—JAK2—central nervous system—acquired immunodeficiency syndrome	0.000212	0.00141	CbGeAlD
Dasatinib—YES1—lung—acquired immunodeficiency syndrome	0.000211	0.00141	CbGeAlD
Dasatinib—STK35—lymph node—acquired immunodeficiency syndrome	0.00021	0.0014	CbGeAlD
Dasatinib—EPHA2—central nervous system—acquired immunodeficiency syndrome	0.000209	0.00139	CbGeAlD
Dasatinib—FYN—central nervous system—acquired immunodeficiency syndrome	0.000209	0.00139	CbGeAlD
Dasatinib—CSK—lymph node—acquired immunodeficiency syndrome	0.000208	0.00139	CbGeAlD
Dasatinib—CSF1R—blood—acquired immunodeficiency syndrome	0.000208	0.00139	CbGeAlD
Dasatinib—PDGFRA—lung—acquired immunodeficiency syndrome	0.000207	0.00138	CbGeAlD
Dasatinib—HCK—lymph node—acquired immunodeficiency syndrome	0.000206	0.00137	CbGeAlD
Dasatinib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.000205	0.00137	CbGeAlD
Dasatinib—ABL2—lymph node—acquired immunodeficiency syndrome	0.000205	0.00136	CbGeAlD
Dasatinib—MAP4K5—central nervous system—acquired immunodeficiency syndrome	0.000204	0.00136	CbGeAlD
Dasatinib—MAP3K3—central nervous system—acquired immunodeficiency syndrome	0.000204	0.00136	CbGeAlD
Dasatinib—SRC—lung—acquired immunodeficiency syndrome	0.000203	0.00135	CbGeAlD
Dasatinib—EPHB6—nervous system—acquired immunodeficiency syndrome	0.000202	0.00135	CbGeAlD
Dasatinib—CSF1R—bone marrow—acquired immunodeficiency syndrome	0.000201	0.00134	CbGeAlD
Dasatinib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.000201	0.00134	CbGeAlD
Dasatinib—CSF1R—spinal cord—acquired immunodeficiency syndrome	0.000201	0.00133	CbGeAlD
Dasatinib—RIPK2—brain—acquired immunodeficiency syndrome	0.0002	0.00133	CbGeAlD
Dasatinib—KIT—digestive system—acquired immunodeficiency syndrome	0.000198	0.00132	CbGeAlD
Dasatinib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.000198	0.00132	CbGeAlD
Dasatinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000197	0.00131	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.000196	0.00131	CbGeAlD
Dasatinib—YES1—nervous system—acquired immunodeficiency syndrome	0.000196	0.0013	CbGeAlD
Dasatinib—SIK1—brain—acquired immunodeficiency syndrome	0.000196	0.0013	CbGeAlD
Dasatinib—EPHB6—central nervous system—acquired immunodeficiency syndrome	0.000195	0.0013	CbGeAlD
Dasatinib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000194	0.00129	CbGeAlD
Dasatinib—EPHA4—brain—acquired immunodeficiency syndrome	0.000194	0.00129	CbGeAlD
Dasatinib—RIPK2—lymph node—acquired immunodeficiency syndrome	0.000193	0.00129	CbGeAlD
Dasatinib—CSF1R—vagina—acquired immunodeficiency syndrome	0.000193	0.00128	CbGeAlD
Dasatinib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000192	0.00128	CbGeAlD
Dasatinib—ERBB3—brain—acquired immunodeficiency syndrome	0.000192	0.00128	CbGeAlD
Dasatinib—MAP3K2—brain—acquired immunodeficiency syndrome	0.00019	0.00126	CbGeAlD
Dasatinib—KIT—blood—acquired immunodeficiency syndrome	0.000189	0.00126	CbGeAlD
Dasatinib—SIK1—lymph node—acquired immunodeficiency syndrome	0.000189	0.00126	CbGeAlD
Dasatinib—YES1—central nervous system—acquired immunodeficiency syndrome	0.000188	0.00125	CbGeAlD
Dasatinib—SRC—nervous system—acquired immunodeficiency syndrome	0.000188	0.00125	CbGeAlD
Dasatinib—EPHA4—lymph node—acquired immunodeficiency syndrome	0.000187	0.00124	CbGeAlD
Dasatinib—MAP2K5—lung—acquired immunodeficiency syndrome	0.000187	0.00124	CbGeAlD
Dasatinib—ERBB3—lymph node—acquired immunodeficiency syndrome	0.000185	0.00123	CbGeAlD
Dasatinib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.000185	0.00123	CbGeAlD
Dasatinib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000185	0.00123	CbGeAlD
Dasatinib—MAP3K2—lymph node—acquired immunodeficiency syndrome	0.000183	0.00122	CbGeAlD
Dasatinib—KIT—bone marrow—acquired immunodeficiency syndrome	0.000183	0.00122	CbGeAlD
Dasatinib—CYP1B1—skin of body—acquired immunodeficiency syndrome	0.000183	0.00122	CbGeAlD
Dasatinib—CSF1R—lung—acquired immunodeficiency syndrome	0.000182	0.00121	CbGeAlD
Dasatinib—KIT—spinal cord—acquired immunodeficiency syndrome	0.000182	0.00121	CbGeAlD
Dasatinib—SRC—central nervous system—acquired immunodeficiency syndrome	0.000181	0.00121	CbGeAlD
Dasatinib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	0.000179	0.00119	CbGeAlD
Dasatinib—MAPK14—brain—acquired immunodeficiency syndrome	0.000178	0.00119	CbGeAlD
Dasatinib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	0.000178	0.00118	CbGeAlD
Dasatinib—FGR—brain—acquired immunodeficiency syndrome	0.000178	0.00118	CbGeAlD
Dasatinib—KIT—vagina—acquired immunodeficiency syndrome	0.000175	0.00117	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000175	0.00116	CbGeAlD
Dasatinib—MAP2K5—nervous system—acquired immunodeficiency syndrome	0.000173	0.00115	CbGeAlD
Dasatinib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000173	0.00115	CbGeAlD
Dasatinib—MAPK14—lymph node—acquired immunodeficiency syndrome	0.000172	0.00115	CbGeAlD
Dasatinib—FGR—lymph node—acquired immunodeficiency syndrome	0.000172	0.00114	CbGeAlD
Dasatinib—LCK—lymph node—acquired immunodeficiency syndrome	0.000172	0.00114	CbGeAlD
Dasatinib—FMO3—brain—acquired immunodeficiency syndrome	0.000172	0.00114	CbGeAlD
Dasatinib—PDGFRB—vagina—acquired immunodeficiency syndrome	0.000171	0.00114	CbGeAlD
Dasatinib—EPHB4—brain—acquired immunodeficiency syndrome	0.000169	0.00113	CbGeAlD
Dasatinib—CSF1R—nervous system—acquired immunodeficiency syndrome	0.000169	0.00112	CbGeAlD
Dasatinib—JAK2—brain—acquired immunodeficiency syndrome	0.000168	0.00112	CbGeAlD
Dasatinib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	0.000167	0.00111	CbGeAlD
Dasatinib—EPHA2—brain—acquired immunodeficiency syndrome	0.000166	0.0011	CbGeAlD
Dasatinib—FMO3—lymph node—acquired immunodeficiency syndrome	0.000166	0.0011	CbGeAlD
Dasatinib—FYN—brain—acquired immunodeficiency syndrome	0.000166	0.0011	CbGeAlD
Dasatinib—KIT—lung—acquired immunodeficiency syndrome	0.000166	0.0011	CbGeAlD
Dasatinib—ABL1—blood—acquired immunodeficiency syndrome	0.000165	0.00109	CbGeAlD
Dasatinib—EPHB4—lymph node—acquired immunodeficiency syndrome	0.000163	0.00109	CbGeAlD
Dasatinib—CSF1R—central nervous system—acquired immunodeficiency syndrome	0.000163	0.00108	CbGeAlD
Dasatinib—JAK2—lymph node—acquired immunodeficiency syndrome	0.000162	0.00108	CbGeAlD
Dasatinib—MAP3K3—brain—acquired immunodeficiency syndrome	0.000162	0.00108	CbGeAlD
Dasatinib—MAP4K5—brain—acquired immunodeficiency syndrome	0.000162	0.00108	CbGeAlD
Dasatinib—PDGFRB—lung—acquired immunodeficiency syndrome	0.000162	0.00108	CbGeAlD
Dasatinib—EPHA2—lymph node—acquired immunodeficiency syndrome	0.00016	0.00107	CbGeAlD
Dasatinib—FYN—lymph node—acquired immunodeficiency syndrome	0.00016	0.00107	CbGeAlD
Dasatinib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000159	0.00106	CbGeAlD
Dasatinib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.000159	0.00105	CbGeAlD
Dasatinib—MAP3K3—lymph node—acquired immunodeficiency syndrome	0.000156	0.00104	CbGeAlD
Dasatinib—MAP4K5—lymph node—acquired immunodeficiency syndrome	0.000156	0.00104	CbGeAlD
Dasatinib—EPHB6—brain—acquired immunodeficiency syndrome	0.000155	0.00103	CbGeAlD
Dasatinib—KIT—nervous system—acquired immunodeficiency syndrome	0.000153	0.00102	CbGeAlD
Dasatinib—ABL1—vagina—acquired immunodeficiency syndrome	0.000153	0.00101	CbGeAlD
Dasatinib—PDGFRB—nervous system—acquired immunodeficiency syndrome	0.00015	0.000997	CbGeAlD
Dasatinib—YES1—brain—acquired immunodeficiency syndrome	0.00015	0.000995	CbGeAlD
Dasatinib—EPHB6—lymph node—acquired immunodeficiency syndrome	0.00015	0.000995	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—acquired immunodeficiency syndrome	0.000148	0.000985	CbGeAlD
Dasatinib—KIT—central nervous system—acquired immunodeficiency syndrome	0.000148	0.000983	CbGeAlD
Dasatinib—PDGFRA—brain—acquired immunodeficiency syndrome	0.000147	0.000976	CbGeAlD
Dasatinib—CYP1B1—digestive system—acquired immunodeficiency syndrome	0.000146	0.000973	CbGeAlD
Dasatinib—YES1—lymph node—acquired immunodeficiency syndrome	0.000145	0.000962	CbGeAlD
Dasatinib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	0.000144	0.00096	CbGeAlD
Dasatinib—ABL1—lung—acquired immunodeficiency syndrome	0.000144	0.00096	CbGeAlD
Dasatinib—SRC—brain—acquired immunodeficiency syndrome	0.000144	0.000957	CbGeAlD
Dasatinib—PDGFRA—lymph node—acquired immunodeficiency syndrome	0.000142	0.000943	CbGeAlD
Dasatinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00014	0.000929	CbGeAlD
Dasatinib—CYP1B1—blood—acquired immunodeficiency syndrome	0.000139	0.000927	CbGeAlD
Dasatinib—SRC—lymph node—acquired immunodeficiency syndrome	0.000139	0.000925	CbGeAlD
Dasatinib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000134	0.000889	CbGeAlD
Dasatinib—MAP2K5—brain—acquired immunodeficiency syndrome	0.000132	0.000881	CbGeAlD
Dasatinib—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000129	0.00086	CbGeAlD
Dasatinib—CSF1R—brain—acquired immunodeficiency syndrome	0.000129	0.00086	CbGeAlD
Dasatinib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000129	0.000856	CbGeAlD
Dasatinib—MAP2K5—lymph node—acquired immunodeficiency syndrome	0.000128	0.000851	CbGeAlD
Dasatinib—CSF1R—lymph node—acquired immunodeficiency syndrome	0.000125	0.000831	CbGeAlD
Dasatinib—CYP1B1—lung—acquired immunodeficiency syndrome	0.000122	0.000813	CbGeAlD
Dasatinib—KIT—brain—acquired immunodeficiency syndrome	0.000117	0.00078	CbGeAlD
Dasatinib—PDGFRB—brain—acquired immunodeficiency syndrome	0.000115	0.000762	CbGeAlD
Dasatinib—KIT—lymph node—acquired immunodeficiency syndrome	0.000113	0.000754	CbGeAlD
Dasatinib—CYP1B1—nervous system—acquired immunodeficiency syndrome	0.000113	0.000753	CbGeAlD
Dasatinib—PDGFRB—lymph node—acquired immunodeficiency syndrome	0.000111	0.000737	CbGeAlD
Dasatinib—CYP1B1—central nervous system—acquired immunodeficiency syndrome	0.000109	0.000725	CbGeAlD
Dasatinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000105	0.000438	CcSEcCtD
Dasatinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000438	CcSEcCtD
Dasatinib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000438	CcSEcCtD
Dasatinib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000105	0.000698	CbGeAlD
Dasatinib—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000437	CcSEcCtD
Dasatinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000437	CcSEcCtD
Dasatinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000437	CcSEcCtD
Dasatinib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000437	CcSEcCtD
Dasatinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000435	CcSEcCtD
Dasatinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000435	CcSEcCtD
Dasatinib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000435	CcSEcCtD
Dasatinib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000434	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000434	CcSEcCtD
Dasatinib—ABCG2—blood—acquired immunodeficiency syndrome	0.000104	0.000691	CbGeAlD
Dasatinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000432	CcSEcCtD
Dasatinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000103	0.000432	CcSEcCtD
Dasatinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000432	CcSEcCtD
Dasatinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000432	CcSEcCtD
Dasatinib—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000432	CcSEcCtD
Dasatinib—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000103	0.000688	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000431	CcSEcCtD
Dasatinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000431	CcSEcCtD
Dasatinib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000428	CcSEcCtD
Dasatinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000428	CcSEcCtD
Dasatinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000428	CcSEcCtD
Dasatinib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000103	0.000428	CcSEcCtD
Dasatinib—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000428	CcSEcCtD
Dasatinib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000426	CcSEcCtD
Dasatinib—ABL1—brain—acquired immunodeficiency syndrome	0.000102	0.000679	CbGeAlD
Dasatinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000426	CcSEcCtD
Dasatinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000426	CcSEcCtD
Dasatinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000102	0.000425	CcSEcCtD
Dasatinib—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000425	CcSEcCtD
Dasatinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000102	0.000424	CcSEcCtD
Dasatinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000102	0.000424	CcSEcCtD
Dasatinib—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000423	CcSEcCtD
Dasatinib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000423	CcSEcCtD
Dasatinib—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000423	CcSEcCtD
Dasatinib—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000422	CcSEcCtD
Dasatinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000101	0.000673	CbGeAlD
Dasatinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.000422	CcSEcCtD
Dasatinib—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.000421	CcSEcCtD
Dasatinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.00042	CcSEcCtD
Dasatinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.00042	CcSEcCtD
Dasatinib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.00042	CcSEcCtD
Dasatinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.0001	0.000668	CbGeAlD
Dasatinib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000419	CcSEcCtD
Dasatinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000419	CcSEcCtD
Dasatinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.0001	0.000418	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000418	CcSEcCtD
Dasatinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.0001	0.000665	CbGeAlD
Dasatinib—CYP1A2—blood—acquired immunodeficiency syndrome	9.99e-05	0.000665	CbGeAlD
Dasatinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	9.98e-05	0.000417	CcSEcCtD
Dasatinib—Discomfort—Saquinavir—acquired immunodeficiency syndrome	9.95e-05	0.000415	CcSEcCtD
Dasatinib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	9.92e-05	0.000414	CcSEcCtD
Dasatinib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	9.89e-05	0.000413	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	9.89e-05	0.000413	CcSEcCtD
Dasatinib—Shock—Ritonavir—acquired immunodeficiency syndrome	9.87e-05	0.000412	CcSEcCtD
Dasatinib—ABL1—lymph node—acquired immunodeficiency syndrome	9.87e-05	0.000657	CbGeAlD
Dasatinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	9.86e-05	0.000411	CcSEcCtD
Dasatinib—CYP1A1—blood—acquired immunodeficiency syndrome	9.85e-05	0.000656	CbGeAlD
Dasatinib—Cough—Lamivudine—acquired immunodeficiency syndrome	9.85e-05	0.000411	CcSEcCtD
Dasatinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	9.85e-05	0.000411	CcSEcCtD
Dasatinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	9.84e-05	0.000411	CcSEcCtD
Dasatinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	9.82e-05	0.00041	CcSEcCtD
Dasatinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	9.82e-05	0.00041	CcSEcCtD
Dasatinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	9.81e-05	0.00041	CcSEcCtD
Dasatinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	9.81e-05	0.00041	CcSEcCtD
Dasatinib—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	9.79e-05	0.000409	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	9.79e-05	0.000409	CcSEcCtD
Dasatinib—Convulsion—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000408	CcSEcCtD
Dasatinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	9.78e-05	0.000408	CcSEcCtD
Dasatinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	9.78e-05	0.000408	CcSEcCtD
Dasatinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	9.75e-05	0.000407	CcSEcCtD
Dasatinib—Confusional state—Saquinavir—acquired immunodeficiency syndrome	9.74e-05	0.000406	CcSEcCtD
Dasatinib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	9.7e-05	0.000405	CcSEcCtD
Dasatinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	9.7e-05	0.000405	CcSEcCtD
Dasatinib—Pain—Efavirenz—acquired immunodeficiency syndrome	9.7e-05	0.000405	CcSEcCtD
Dasatinib—Rash—Nevirapine—acquired immunodeficiency syndrome	9.7e-05	0.000405	CcSEcCtD
Dasatinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	9.69e-05	0.000404	CcSEcCtD
Dasatinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	9.67e-05	0.000404	CcSEcCtD
Dasatinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	9.67e-05	0.000404	CcSEcCtD
Dasatinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	9.66e-05	0.000403	CcSEcCtD
Dasatinib—Somnolence—Delavirdine—acquired immunodeficiency syndrome	9.65e-05	0.000403	CcSEcCtD
Dasatinib—Headache—Nevirapine—acquired immunodeficiency syndrome	9.63e-05	0.000402	CcSEcCtD
Dasatinib—CYP3A5—blood—acquired immunodeficiency syndrome	9.63e-05	0.000641	CbGeAlD
Dasatinib—ABCG2—vagina—acquired immunodeficiency syndrome	9.62e-05	0.00064	CbGeAlD
Dasatinib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	9.61e-05	0.000401	CcSEcCtD
Dasatinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	9.61e-05	0.000401	CcSEcCtD
Dasatinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	9.61e-05	0.000401	CcSEcCtD
Dasatinib—Infection—Saquinavir—acquired immunodeficiency syndrome	9.59e-05	0.0004	CcSEcCtD
Dasatinib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	9.58e-05	0.0004	CcSEcCtD
Dasatinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	9.56e-05	0.000399	CcSEcCtD
Dasatinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	9.55e-05	0.000399	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	9.54e-05	0.000398	CcSEcCtD
Dasatinib—Urticaria—Indinavir—acquired immunodeficiency syndrome	9.53e-05	0.000398	CcSEcCtD
Dasatinib—Shock—Saquinavir—acquired immunodeficiency syndrome	9.5e-05	0.000397	CcSEcCtD
Dasatinib—Discomfort—Lamivudine—acquired immunodeficiency syndrome	9.5e-05	0.000396	CcSEcCtD
Dasatinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	9.49e-05	0.000396	CcSEcCtD
Dasatinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	9.49e-05	0.000396	CcSEcCtD
Dasatinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	9.47e-05	0.000395	CcSEcCtD
Dasatinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	9.47e-05	0.000395	CcSEcCtD
Dasatinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	9.46e-05	0.000395	CcSEcCtD
Dasatinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	9.44e-05	0.000394	CcSEcCtD
Dasatinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	9.43e-05	0.000394	CcSEcCtD
Dasatinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	9.39e-05	0.000392	CcSEcCtD
Dasatinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	9.38e-05	0.000392	CcSEcCtD
Dasatinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	9.38e-05	0.000392	CcSEcCtD
Dasatinib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	9.38e-05	0.000391	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	9.37e-05	0.000391	CcSEcCtD
Dasatinib—Rash—Stavudine—acquired immunodeficiency syndrome	9.36e-05	0.000391	CcSEcCtD
Dasatinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	9.35e-05	0.00039	CcSEcCtD
Dasatinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	9.35e-05	0.00039	CcSEcCtD
Dasatinib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	9.34e-05	0.00039	CcSEcCtD
Dasatinib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	9.34e-05	0.00039	CcSEcCtD
Dasatinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	9.33e-05	0.000389	CcSEcCtD
Dasatinib—Headache—Stavudine—acquired immunodeficiency syndrome	9.3e-05	0.000388	CcSEcCtD
Dasatinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.3e-05	0.000388	CcSEcCtD
Dasatinib—Confusional state—Lamivudine—acquired immunodeficiency syndrome	9.29e-05	0.000388	CcSEcCtD
Dasatinib—Pain—Delavirdine—acquired immunodeficiency syndrome	9.28e-05	0.000387	CcSEcCtD
Dasatinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.28e-05	0.000387	CcSEcCtD
Dasatinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.27e-05	0.000387	CcSEcCtD
Dasatinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.26e-05	0.000386	CcSEcCtD
Dasatinib—Rash—Abacavir—acquired immunodeficiency syndrome	9.22e-05	0.000385	CcSEcCtD
Dasatinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.21e-05	0.000385	CcSEcCtD
Dasatinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.21e-05	0.000385	CcSEcCtD
Dasatinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.21e-05	0.000384	CcSEcCtD
Dasatinib—Headache—Abacavir—acquired immunodeficiency syndrome	9.16e-05	0.000382	CcSEcCtD
Dasatinib—Infection—Lamivudine—acquired immunodeficiency syndrome	9.15e-05	0.000382	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.14e-05	0.000382	CcSEcCtD
Dasatinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.13e-05	0.000381	CcSEcCtD
Dasatinib—CYP1A1—vagina—acquired immunodeficiency syndrome	9.13e-05	0.000608	CbGeAlD
Dasatinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.13e-05	0.000381	CcSEcCtD
Dasatinib—ABCG2—lung—acquired immunodeficiency syndrome	9.1e-05	0.000605	CbGeAlD
Dasatinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.07e-05	0.000379	CcSEcCtD
Dasatinib—Shock—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.000378	CcSEcCtD
Dasatinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.03e-05	0.000377	CcSEcCtD
Dasatinib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	9.02e-05	0.000377	CcSEcCtD
Dasatinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	9.02e-05	0.000376	CcSEcCtD
Dasatinib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.01e-05	0.000376	CcSEcCtD
Dasatinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	8.96e-05	0.000374	CcSEcCtD
Dasatinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	8.96e-05	0.000374	CcSEcCtD
Dasatinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	8.95e-05	0.000373	CcSEcCtD
Dasatinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	8.95e-05	0.000373	CcSEcCtD
Dasatinib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	8.94e-05	0.000373	CcSEcCtD
Dasatinib—CYP3A5—vagina—acquired immunodeficiency syndrome	8.93e-05	0.000594	CbGeAlD
Dasatinib—Somnolence—Ritonavir—acquired immunodeficiency syndrome	8.92e-05	0.000372	CcSEcCtD
Dasatinib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	8.91e-05	0.000372	CcSEcCtD
Dasatinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	8.87e-05	0.00037	CcSEcCtD
Dasatinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	8.85e-05	0.000369	CcSEcCtD
Dasatinib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	8.84e-05	0.000369	CcSEcCtD
Dasatinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	8.83e-05	0.000369	CcSEcCtD
Dasatinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	8.83e-05	0.000369	CcSEcCtD
Dasatinib—Nausea—Stavudine—acquired immunodeficiency syndrome	8.82e-05	0.000368	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	8.8e-05	0.000367	CcSEcCtD
Dasatinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	8.78e-05	0.000367	CcSEcCtD
Dasatinib—CYP1A2—lung—acquired immunodeficiency syndrome	8.75e-05	0.000583	CbGeAlD
Dasatinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	8.73e-05	0.000365	CcSEcCtD
Dasatinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	8.72e-05	0.000364	CcSEcCtD
Dasatinib—Nausea—Abacavir—acquired immunodeficiency syndrome	8.69e-05	0.000363	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	8.66e-05	0.000362	CcSEcCtD
Dasatinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	8.65e-05	0.000361	CcSEcCtD
Dasatinib—CYP1B1—brain—acquired immunodeficiency syndrome	8.65e-05	0.000575	CbGeAlD
Dasatinib—CYP1A1—lung—acquired immunodeficiency syndrome	8.64e-05	0.000575	CbGeAlD
Dasatinib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	8.62e-05	0.00036	CcSEcCtD
Dasatinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	8.61e-05	0.000359	CcSEcCtD
Dasatinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	8.61e-05	0.000359	CcSEcCtD
Dasatinib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	8.61e-05	0.000359	CcSEcCtD
Dasatinib—Somnolence—Saquinavir—acquired immunodeficiency syndrome	8.59e-05	0.000358	CcSEcCtD
Dasatinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	8.58e-05	0.000358	CcSEcCtD
Dasatinib—Pain—Ritonavir—acquired immunodeficiency syndrome	8.58e-05	0.000358	CcSEcCtD
Dasatinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	8.58e-05	0.000358	CcSEcCtD
Dasatinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	8.58e-05	0.000358	CcSEcCtD
Dasatinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	8.53e-05	0.000356	CcSEcCtD
Dasatinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	8.5e-05	0.000355	CcSEcCtD
Dasatinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	8.49e-05	0.000354	CcSEcCtD
Dasatinib—CYP3A5—lung—acquired immunodeficiency syndrome	8.44e-05	0.000562	CbGeAlD
Dasatinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.39e-05	0.00035	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.39e-05	0.00035	CcSEcCtD
Dasatinib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.35e-05	0.000349	CcSEcCtD
Dasatinib—CYP1B1—lymph node—acquired immunodeficiency syndrome	8.35e-05	0.000556	CbGeAlD
Dasatinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.34e-05	0.000348	CcSEcCtD
Dasatinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	8.33e-05	0.000348	CcSEcCtD
Dasatinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.33e-05	0.000348	CcSEcCtD
Dasatinib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	8.27e-05	0.000345	CcSEcCtD
Dasatinib—Pain—Saquinavir—acquired immunodeficiency syndrome	8.26e-05	0.000345	CcSEcCtD
Dasatinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.26e-05	0.000345	CcSEcCtD
Dasatinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.21e-05	0.000343	CcSEcCtD
Dasatinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.21e-05	0.000343	CcSEcCtD
Dasatinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.21e-05	0.000342	CcSEcCtD
Dasatinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.2e-05	0.000342	CcSEcCtD
Dasatinib—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.19e-05	0.000342	CcSEcCtD
Dasatinib—Rash—Zidovudine—acquired immunodeficiency syndrome	8.14e-05	0.00034	CcSEcCtD
Dasatinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.14e-05	0.00034	CcSEcCtD
Dasatinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.13e-05	0.000339	CcSEcCtD
Dasatinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.11e-05	0.000338	CcSEcCtD
Dasatinib—Headache—Zidovudine—acquired immunodeficiency syndrome	8.08e-05	0.000337	CcSEcCtD
Dasatinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.02e-05	0.000335	CcSEcCtD
Dasatinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.01e-05	0.000334	CcSEcCtD
Dasatinib—CYP1A1—nervous system—acquired immunodeficiency syndrome	8e-05	0.000532	CbGeAlD
Dasatinib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	7.99e-05	0.000334	CcSEcCtD
Dasatinib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	7.97e-05	0.000333	CcSEcCtD
Dasatinib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	7.96e-05	0.000332	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	7.95e-05	0.000332	CcSEcCtD
Dasatinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	7.94e-05	0.000332	CcSEcCtD
Dasatinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	7.94e-05	0.000331	CcSEcCtD
Dasatinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	7.93e-05	0.000331	CcSEcCtD
Dasatinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	7.93e-05	0.000331	CcSEcCtD
Dasatinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	7.9e-05	0.00033	CcSEcCtD
Dasatinib—Pain—Lamivudine—acquired immunodeficiency syndrome	7.88e-05	0.000329	CcSEcCtD
Dasatinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	7.88e-05	0.000329	CcSEcCtD
Dasatinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	7.78e-05	0.000325	CcSEcCtD
Dasatinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	7.76e-05	0.000324	CcSEcCtD
Dasatinib—CYP1A1—central nervous system—acquired immunodeficiency syndrome	7.7e-05	0.000512	CbGeAlD
Dasatinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	7.68e-05	0.00032	CcSEcCtD
Dasatinib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	7.67e-05	0.00032	CcSEcCtD
Dasatinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	7.67e-05	0.00032	CcSEcCtD
Dasatinib—ABCB1—retina—acquired immunodeficiency syndrome	7.65e-05	0.000509	CbGeAlD
Dasatinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	7.63e-05	0.000319	CcSEcCtD
Dasatinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	7.63e-05	0.000319	CcSEcCtD
Dasatinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	7.63e-05	0.000319	CcSEcCtD
Dasatinib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	7.59e-05	0.000317	CcSEcCtD
Dasatinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	7.59e-05	0.000505	CbGeAlD
Dasatinib—Rash—Indinavir—acquired immunodeficiency syndrome	7.57e-05	0.000316	CcSEcCtD
Dasatinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	7.56e-05	0.000316	CcSEcCtD
Dasatinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	7.53e-05	0.000314	CcSEcCtD
Dasatinib—Headache—Indinavir—acquired immunodeficiency syndrome	7.52e-05	0.000314	CcSEcCtD
Dasatinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	7.5e-05	0.000313	CcSEcCtD
Dasatinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.42e-05	0.00031	CcSEcCtD
Dasatinib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.39e-05	0.000309	CcSEcCtD
Dasatinib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.32e-05	0.000305	CcSEcCtD
Dasatinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.28e-05	0.000304	CcSEcCtD
Dasatinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.28e-05	0.000304	CcSEcCtD
Dasatinib—CYP3A4—blood—acquired immunodeficiency syndrome	7.23e-05	0.000481	CbGeAlD
Dasatinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.21e-05	0.000301	CcSEcCtD
Dasatinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.2e-05	0.0003	CcSEcCtD
Dasatinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.17e-05	0.000299	CcSEcCtD
Dasatinib—Rash—Efavirenz—acquired immunodeficiency syndrome	7.15e-05	0.000298	CcSEcCtD
Dasatinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.14e-05	0.000298	CcSEcCtD
Dasatinib—Nausea—Indinavir—acquired immunodeficiency syndrome	7.13e-05	0.000298	CcSEcCtD
Dasatinib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.11e-05	0.000297	CcSEcCtD
Dasatinib—Headache—Efavirenz—acquired immunodeficiency syndrome	7.1e-05	0.000297	CcSEcCtD
Dasatinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.1e-05	0.000296	CcSEcCtD
Dasatinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.93e-05	0.000289	CcSEcCtD
Dasatinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	6.9e-05	0.000288	CcSEcCtD
Dasatinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.86e-05	0.000287	CcSEcCtD
Dasatinib—Rash—Delavirdine—acquired immunodeficiency syndrome	6.84e-05	0.000286	CcSEcCtD
Dasatinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.83e-05	0.000285	CcSEcCtD
Dasatinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	6.83e-05	0.000285	CcSEcCtD
Dasatinib—Headache—Delavirdine—acquired immunodeficiency syndrome	6.8e-05	0.000284	CcSEcCtD
Dasatinib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	6.79e-05	0.000283	CcSEcCtD
Dasatinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	6.74e-05	0.000281	CcSEcCtD
Dasatinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	6.63e-05	0.000277	CcSEcCtD
Dasatinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	6.61e-05	0.000276	CcSEcCtD
Dasatinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	6.61e-05	0.000276	CcSEcCtD
Dasatinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.52e-05	0.000272	CcSEcCtD
Dasatinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.44e-05	0.000269	CcSEcCtD
Dasatinib—ABCG2—brain—acquired immunodeficiency syndrome	6.44e-05	0.000428	CbGeAlD
Dasatinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.39e-05	0.000267	CcSEcCtD
Dasatinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.38e-05	0.000266	CcSEcCtD
Dasatinib—Rash—Ritonavir—acquired immunodeficiency syndrome	6.33e-05	0.000264	CcSEcCtD
Dasatinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.32e-05	0.000264	CcSEcCtD
Dasatinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.3e-05	0.000263	CcSEcCtD
Dasatinib—Headache—Ritonavir—acquired immunodeficiency syndrome	6.29e-05	0.000262	CcSEcCtD
Dasatinib—ABCG2—lymph node—acquired immunodeficiency syndrome	6.22e-05	0.000414	CbGeAlD
Dasatinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.14e-05	0.000256	CcSEcCtD
Dasatinib—CYP1A1—brain—acquired immunodeficiency syndrome	6.11e-05	0.000407	CbGeAlD
Dasatinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.09e-05	0.000254	CcSEcCtD
Dasatinib—Rash—Saquinavir—acquired immunodeficiency syndrome	6.09e-05	0.000254	CcSEcCtD
Dasatinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.08e-05	0.000254	CcSEcCtD
Dasatinib—Headache—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000253	CcSEcCtD
Dasatinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.96e-05	0.000249	CcSEcCtD
Dasatinib—CYP1A1—lymph node—acquired immunodeficiency syndrome	5.91e-05	0.000393	CbGeAlD
Dasatinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	5.87e-05	0.00039	CbGeAlD
Dasatinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000244	CcSEcCtD
Dasatinib—Rash—Lamivudine—acquired immunodeficiency syndrome	5.81e-05	0.000242	CcSEcCtD
Dasatinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.8e-05	0.000242	CcSEcCtD
Dasatinib—Headache—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.000241	CcSEcCtD
Dasatinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.74e-05	0.000239	CcSEcCtD
Dasatinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	5.65e-05	0.000376	CbGeAlD
Dasatinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.47e-05	0.000228	CcSEcCtD
Dasatinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	5.44e-05	0.000362	CbGeAlD
Dasatinib—ABCB1—digestive system—acquired immunodeficiency syndrome	5.37e-05	0.000357	CbGeAlD
Dasatinib—ABCB1—blood—acquired immunodeficiency syndrome	5.12e-05	0.00034	CbGeAlD
Dasatinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	4.95e-05	0.000329	CbGeAlD
Dasatinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	4.93e-05	0.000328	CbGeAlD
Dasatinib—ABCB1—vagina—acquired immunodeficiency syndrome	4.74e-05	0.000316	CbGeAlD
Dasatinib—ABCB1—lung—acquired immunodeficiency syndrome	4.49e-05	0.000298	CbGeAlD
Dasatinib—ABCB1—nervous system—acquired immunodeficiency syndrome	4.15e-05	0.000276	CbGeAlD
Dasatinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	4e-05	0.000266	CbGeAlD
Dasatinib—ABCB1—brain—acquired immunodeficiency syndrome	3.17e-05	0.000211	CbGeAlD
Dasatinib—ABCB1—lymph node—acquired immunodeficiency syndrome	3.07e-05	0.000204	CbGeAlD
Dasatinib—JAK2—Immune System—CD8A—acquired immunodeficiency syndrome	1.16e-05	9.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CSF2—acquired immunodeficiency syndrome	1.16e-05	9.41e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.15e-05	9.4e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.15e-05	9.37e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IFNA1—acquired immunodeficiency syndrome	1.15e-05	9.32e-05	CbGpPWpGaD
Dasatinib—RIPK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.14e-05	9.29e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.14e-05	9.28e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.14e-05	9.26e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.13e-05	9.23e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL2—acquired immunodeficiency syndrome	1.13e-05	9.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HLA-B—acquired immunodeficiency syndrome	1.13e-05	9.17e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IFNG—acquired immunodeficiency syndrome	1.12e-05	9.14e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.12e-05	9.08e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.12e-05	9.08e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—ALB—acquired immunodeficiency syndrome	1.11e-05	9.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HLA-B—acquired immunodeficiency syndrome	1.11e-05	9.05e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD79A—acquired immunodeficiency syndrome	1.11e-05	9.05e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CXCR4—acquired immunodeficiency syndrome	1.1e-05	8.99e-05	CbGpPWpGaD
Dasatinib—JAK2—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.1e-05	8.95e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.09e-05	8.91e-05	CbGpPWpGaD
Dasatinib—FGR—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.09e-05	8.91e-05	CbGpPWpGaD
Dasatinib—SRC—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.09e-05	8.87e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.09e-05	8.86e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.09e-05	8.86e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL2—acquired immunodeficiency syndrome	1.09e-05	8.86e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.09e-05	8.85e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL2—acquired immunodeficiency syndrome	1.08e-05	8.83e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—CD4—acquired immunodeficiency syndrome	1.08e-05	8.82e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.08e-05	8.8e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.07e-05	8.75e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.07e-05	8.72e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.07e-05	8.68e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.07e-05	8.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	1.07e-05	8.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.06e-05	8.64e-05	CbGpPWpGaD
Dasatinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.05e-05	8.59e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.05e-05	8.54e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.05e-05	8.54e-05	CbGpPWpGaD
Dasatinib—LYN—Axon guidance—IL6—acquired immunodeficiency syndrome	1.04e-05	8.51e-05	CbGpPWpGaD
Dasatinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	1.04e-05	8.47e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.04e-05	8.47e-05	CbGpPWpGaD
Dasatinib—FYN—Axon guidance—IL6—acquired immunodeficiency syndrome	1.03e-05	8.38e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.03e-05	8.36e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CCR5—acquired immunodeficiency syndrome	1.03e-05	8.36e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	1.02e-05	8.34e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	1.02e-05	8.31e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	1.01e-05	8.24e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	1.01e-05	8.24e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.01e-05	8.24e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.01e-05	8.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.01e-05	8.22e-05	CbGpPWpGaD
Dasatinib—ERBB3—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.01e-05	8.19e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—CD4—acquired immunodeficiency syndrome	1e-05	8.15e-05	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1e-05	8.14e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.98e-06	8.13e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.97e-06	8.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.97e-06	8.12e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL2—acquired immunodeficiency syndrome	9.97e-06	8.12e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IFNG—acquired immunodeficiency syndrome	9.85e-06	8.02e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.79e-06	7.98e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.79e-06	7.97e-05	CbGpPWpGaD
Dasatinib—JAK2—Axon guidance—IL6—acquired immunodeficiency syndrome	9.78e-06	7.96e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CCR5—acquired immunodeficiency syndrome	9.76e-06	7.95e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	9.74e-06	7.93e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.71e-06	7.9e-05	CbGpPWpGaD
Dasatinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	9.63e-06	7.84e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.58e-06	7.8e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.56e-06	7.79e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—CD4—acquired immunodeficiency syndrome	9.51e-06	7.75e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.46e-06	7.71e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	9.44e-06	7.69e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.29e-06	7.56e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	9.24e-06	7.52e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	9.2e-06	7.49e-05	CbGpPWpGaD
Dasatinib—CSK—Immune System—IL6—acquired immunodeficiency syndrome	9.19e-06	7.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.19e-06	7.48e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	9.1e-06	7.41e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.09e-06	7.4e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD40LG—acquired immunodeficiency syndrome	9.06e-06	7.38e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.05e-06	7.37e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—IL2—acquired immunodeficiency syndrome	9.03e-06	7.35e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD8A—acquired immunodeficiency syndrome	8.96e-06	7.3e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CSF2—acquired immunodeficiency syndrome	8.96e-06	7.3e-05	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—IL6—acquired immunodeficiency syndrome	8.9e-06	7.25e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—CD4—acquired immunodeficiency syndrome	8.84e-06	7.2e-05	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.83e-06	7.19e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	8.8e-06	7.16e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—TNF—acquired immunodeficiency syndrome	8.76e-06	7.13e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL2—acquired immunodeficiency syndrome	8.75e-06	7.13e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.75e-06	7.12e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.73e-06	7.11e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.73e-06	7.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	8.65e-06	7.04e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—HLA-B—acquired immunodeficiency syndrome	8.62e-06	7.02e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	8.55e-06	6.96e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	8.49e-06	6.92e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—IL6—acquired immunodeficiency syndrome	8.49e-06	6.91e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	8.49e-06	6.91e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	8.48e-06	6.91e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.44e-06	6.87e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—IL6—acquired immunodeficiency syndrome	8.38e-06	6.82e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	8.33e-06	6.78e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.28e-06	6.74e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.28e-06	6.74e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.22e-06	6.7e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—IL6—acquired immunodeficiency syndrome	8.22e-06	6.69e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.15e-06	6.64e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.11e-06	6.6e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	8.04e-06	6.55e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	8.03e-06	6.53e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.98e-06	6.5e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.98e-06	6.5e-05	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—IL6—acquired immunodeficiency syndrome	7.91e-06	6.44e-05	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.89e-06	6.42e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.86e-06	6.4e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—CD4—acquired immunodeficiency syndrome	7.84e-06	6.39e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	7.82e-06	6.36e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.73e-06	6.3e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.73e-06	6.3e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—IL6—acquired immunodeficiency syndrome	7.69e-06	6.26e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.68e-06	6.26e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.59e-06	6.18e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—IL6—acquired immunodeficiency syndrome	7.58e-06	6.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.57e-06	6.16e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CCR5—acquired immunodeficiency syndrome	7.57e-06	6.16e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.51e-06	6.12e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	7.5e-06	6.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.47e-06	6.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.47e-06	6.08e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.46e-06	6.07e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.46e-06	6.07e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	7.42e-06	6.05e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.42e-06	6.04e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	7.4e-06	6.02e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.36e-06	5.99e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	7.34e-06	5.98e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.34e-06	5.98e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.31e-06	5.95e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	7.31e-06	5.95e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.3e-06	5.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	7.24e-06	5.9e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IFNG—acquired immunodeficiency syndrome	7.23e-06	5.89e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.19e-06	5.85e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	7.09e-06	5.78e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.07e-06	5.76e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	7.06e-06	5.75e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—acquired immunodeficiency syndrome	7.06e-06	5.75e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD4—acquired immunodeficiency syndrome	6.98e-06	5.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	6.98e-06	5.68e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IFNG—acquired immunodeficiency syndrome	6.96e-06	5.67e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.92e-06	5.64e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IFNG—acquired immunodeficiency syndrome	6.87e-06	5.6e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.83e-06	5.56e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.73e-06	5.48e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD4—acquired immunodeficiency syndrome	6.72e-06	5.47e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—acquired immunodeficiency syndrome	6.71e-06	5.46e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	6.69e-06	5.45e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.69e-06	5.45e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.68e-06	5.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	6.67e-06	5.43e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—acquired immunodeficiency syndrome	6.65e-06	5.41e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.64e-06	5.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD4—acquired immunodeficiency syndrome	6.64e-06	5.4e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.59e-06	5.36e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.56e-06	5.34e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.54e-06	5.33e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	6.53e-06	5.31e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—acquired immunodeficiency syndrome	6.52e-06	5.31e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	6.5e-06	5.29e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.48e-06	5.28e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CD4—acquired immunodeficiency syndrome	6.45e-06	5.25e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.45e-06	5.25e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL2—acquired immunodeficiency syndrome	6.42e-06	5.23e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	6.39e-06	5.21e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—acquired immunodeficiency syndrome	6.37e-06	5.19e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.24e-06	5.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL2—acquired immunodeficiency syndrome	6.19e-06	5.04e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.16e-06	5.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CD4—acquired immunodeficiency syndrome	6.13e-06	4.99e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL2—acquired immunodeficiency syndrome	6.11e-06	4.97e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	6.02e-06	4.9e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.99e-06	4.87e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.94e-06	4.84e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.88e-06	4.79e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—acquired immunodeficiency syndrome	5.86e-06	4.77e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	5.81e-06	4.73e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.79e-06	4.72e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.76e-06	4.69e-05	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.7e-06	4.64e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.66e-06	4.61e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—ALB—acquired immunodeficiency syndrome	5.43e-06	4.42e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.41e-06	4.41e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—acquired immunodeficiency syndrome	5.41e-06	4.41e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.4e-06	4.4e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	5.37e-06	4.37e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	5.35e-06	4.36e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IFNG—acquired immunodeficiency syndrome	5.33e-06	4.34e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.3e-06	4.31e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD4—acquired immunodeficiency syndrome	5.15e-06	4.19e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—acquired immunodeficiency syndrome	5.14e-06	4.19e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.05e-06	4.11e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	4.94e-06	4.02e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.79e-06	3.9e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.78e-06	3.9e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.78e-06	3.89e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CD4—acquired immunodeficiency syndrome	4.75e-06	3.87e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL2—acquired immunodeficiency syndrome	4.74e-06	3.86e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	4.59e-06	3.74e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	4.35e-06	3.54e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.31e-06	3.51e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.3e-06	3.5e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—acquired immunodeficiency syndrome	4.24e-06	3.45e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.22e-06	3.44e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.15e-06	3.38e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	4.02e-06	3.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4e-06	3.26e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.95e-06	3.22e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.93e-06	3.2e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.93e-06	3.2e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	3.92e-06	3.19e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	3.84e-06	3.12e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	3.82e-06	3.11e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.79e-06	3.09e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—acquired immunodeficiency syndrome	3.78e-06	3.07e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—acquired immunodeficiency syndrome	3.64e-06	2.96e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	3.62e-06	2.95e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—acquired immunodeficiency syndrome	3.59e-06	2.92e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.54e-06	2.88e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—acquired immunodeficiency syndrome	3.49e-06	2.84e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.46e-06	2.82e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.34e-06	2.72e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.33e-06	2.71e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—acquired immunodeficiency syndrome	3.31e-06	2.7e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	3.14e-06	2.56e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.06e-06	2.49e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.97e-06	2.42e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	2.9e-06	2.36e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.81e-06	2.29e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—acquired immunodeficiency syndrome	2.78e-06	2.27e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.67e-06	2.18e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—acquired immunodeficiency syndrome	2.57e-06	2.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.53e-06	2.06e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.48e-06	2.02e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.44e-06	1.99e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.35e-06	1.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.32e-06	1.89e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.13e-06	1.74e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.03e-06	1.66e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.8e-06	1.47e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.65e-06	1.34e-05	CbGpPWpGaD
